Pharmaceutical Industry News Archive
Get news by email or subscribe to our news feeds.
News Archive for February 2007
February 1, 2007
- AstraZeneca Acquires Arrow Therapeutics To Broaden Anti-Infective Capabilities
- AstraZeneca PLC - Fourth Quarter and Full Year Results 2006
- Court Rules In Pfizer's Favor In Norvasc Patent Case, Finds Synthon Obtained Patent By Inequitable Conduct
- Fresenius Medical Care and Amgen Enter New Commercial Collaboration in Europe
- Fresenius Medical Care and Amgen Establish a Joint Research Program in Europe
- FDA Sends MGI Pharma Letter Over Gliadel Wafer Advertisement
- Ligand Announces Corporate Restructuring
- Conor Medsystems Stockholders Approve Merger Agreement with Johnson & Johnson
- Strides Arcolab's JV acquires Farma Plus, Norway
- Intellect Neurosciences, Inc. Converts into a Public Company Through Merger Transaction with GlobePan Resources, Inc.
- Alembic Acquires Non-Oncology Business of Dabur Pharma Ltd.
- Pfizer to Acquire BioRexis to Access Novel Technology Platform and Early Stage Diabetes Pipeline
- FDA Announces Important Changes to Fuzeon Product Labeling
- Astellas Will Offer an Early Retirement Program to Japanese Employees
- Grifols Announces FDA Approval of Alphanate to Treat von Willebrand Disease
- EaglePicher Pharmaceutical Services Acquired by Aptuit
- Hospira Completes Acquisition of Mayne Pharma, Announces New Commercial Leadership Structure
February 2, 2007
- Numira Biosciences and Visual Influence Announce Merger
- Eli Lilly Japan and Shionogi to Co-Develop and Co-Market Duloxetine in Japan
- GlaxoSmithKline Receives Approvable Letter for New Indications for Arixtra (Fondaparinux Sodium) Injection
- Accelrys Announces Pfizer Inc. as the First Member of the Enterprise Cheminformatics Consortium
- CSL Behring and Bayer Extend Agreement for Supply of Helixate Recombinant Coagulation Factor
- Texas Hormone Therapy Lawsuit Has Been Dismissed
- Anacor Signs Worldwide Exclusive License Agreement With Schering-Plough for AN2690, a New Topical Anti-Fungal Treatment
- GTx's Phase III Clinical Development of Acapodene on Course Following Planned Safety Review
- FDA MedWatch - Lucentis (ranibizumab injection) - Preliminary Safety Information From a Planned Interim Analysis In an On-Going Study (SAILOR Study)
- China Health Holding Acquires Majority Stake in Beijing Boran Pharmaceutical
- Schering-Plough Cites Today's Anacor Agreement as Latest in Series of Deals
- Valtrex (valacyclovir) - US Patent Litigation Update
- Mitsubishi Pharma Corporation Reaches a Basic Agreement to Merge with Tanabe Seiyaku Co., Ltd.
- FDA Approves New Dosing Recommendations for Rapamune in High Immunologic Risk Renal Transplant Patients
- All Global is Acquired by WPP
- Common Blood Pressure Drug Reduces Progressive Muscle Degeneration in Mice
February 5, 2007
- Arena Pharmaceuticals Completes Enrollment with 3,182 Patients in Lorcaserin Phase 3 Trial for Obesity
- Wyeth Pharmaceuticals and Nautilus Biotech Announce Collaboration to Develop Hemophilia Therapies
- AstraZeneca Licenses Regeneron's VelocImmune Technology for Discovering Human Monoclonal Antibodies
- ImClone Systems Incorporated and Bristol-Myers Squibb Announce Application In Japan for Use of Erbitux in Metastatic Colorectal Cancer
- Roche Continues to Strengthen Research and Development Focus on Disease Biology Areas to Enhance Alignment of R&D
- elbion and Wyeth Enter Collaboration to Develop New Treatments for Schizophrenia
- UTEK Corporation and CytoDyn, Inc. Complete Technology Transfer
- Impax Files Revised Submission with Office of the Chief Accountant of the SEC
- Phase III Trial of Progesterone for the Prevention of Preterm Birth in Women with a Previous Preterm Birth Earlier than 35 Weeks Does Not Meet Endpoints
- Wyeth Pharmaceuticals and MediVas Announce Research Partnership to Develop Advanced Hemophilia Therapies
- AXM Pharma Announces Acquisition of Leading Chinese Research Institute
- Mitsubishi Chemical Holdings: Business Results for the Third Quarter of the Fiscal Year Ending March 31, 2007
- President’s FY 2008 Budget Advances FDA’s Public Health Goals, Including Improving Safety of Nation’s Food Supply
February 6, 2007
- ImClone Systems Opts-out of Development Agreement with UCB to Focus Resources on Proprietary, Anti-VEGFr-2 Antibody IMC-1121B
- ViaCell Announces CB001 Phase I Results
- KineMed and Bayer Healthcare AG Enter Collaboration to Discover New Therapeutic Applications for Drug Candidates
- Migenix Provides Update on License-Option Agreement with Schering-Plough for Celgosivir in Hepatitis C
- Eisai Confirms Application for Judicial Review of NICE
- Laureate Pharma Announces Collaboration With Boehringer Ingelheim
- Genta Announces the Company Will Appeal FDA Action on New Drug Application of Genasense in Chronic Lymphocytic Leukemia
- UCB Gains Global Rights Pertaining to VEGFR-2 for CDP-791
- Global Agreement for HuMax-CD20 Receives Antitrust Clearance
- Abbott to Initiate First Study to Evaluate Xience V Everolimus Eluting Coronary Stent System in Treatment of Women with Cardiovascular Disease
- WEHI Enters Research Collaboration With Genentech to Develop New Cancer Drugs
- Ranbaxy Signs a New R&D Agreement with GSK
- Orion Updates Progress with Simdax (i.v. levosimendan)
- Jerini Expands Collaboration with Baxter to Develop Non-intraveneous Hemophilia Therapy
- Abbott Statement Regarding CMS' Proposed Expansion of Coverage for Carotid Artery Stenting
- Bio-Imaging Completes the Acquisition of Theralys SA of Lyon, France
- Strategic Planning for Discovery, Development and Clinical Operations in China, India and other Emerging Regions
February 7, 2007
- Forest Laboratories Announces Termination of Agreement for Faropenem
- Roche Posts Outstanding Results for 2006
- FDA Public Health Advisory: Life-Threatening Side Effects with the Use of Skin Products Containing Numbing Ingredients for Cosmetic Procedures
- Drug Used in Coronary Artery Bypass Graft Surgery May Increase Risk of Death
- Return on Investment for Pediatric Exclusivity Program Varies Widely for Pharmaceutical Companies
- Inex Pharmaceuticals Announces Court of Appeal Win
- Replidyne and Forest End Faropenem Collaboration
- Baxter Receives Clearance From U.S. FDA for Ipump Pain Management System 510(k)
- Bayer Responds to Study and Commentary Published in Journal of American Medical Association
- Cambrex Completes Sale of Bio Businesses
- Celtic Pharma Terminates Transmid Trial KSB311R/CIII/001
- GlaxoSmithKline Accepts Shares in Tender Offer for Shares of Praecis Pharmaceuticals and Commences Subsequent Offering Period
- IACP Calls on NAMS to Disclose Financial Ties to Wyeth
- New Analysis Shows That Intensive Lipitor Therapy Cuts the Risk of Hospitalizations Due to Heart Failure in Patients with Coronary Heart Disease
- Polydex Pharmaceuticals Issues Interim Report on Business Operations
- CDC, FAA, NIH, FDA, FBI and USDA Get the Highest Ratings of Thirteen Federal Government Agencies
February 8, 2007
- FDA Approves Orlistat for Over-the-Counter Use
- Centocor, Inc. Releases Phase 2 Data on Novel Biologic CNTO 1275 Targeting Chronic Plaque Psoriasis
- Glaxosmithkline and Fabre-Kramer Pharmaceuticals Enter Global Agreement for New Treatment of Major Depressive Disorder
- Baxter Continues Collaborations With Global Health Authorities to Advance Pandemic Preparedness
- Daiichi Sankyo Returns Development Rights of KAI-9803
- FDA Approves alli (orlistat 60 mg capsules) Over-The-Counter
- Standard Therapy More Effective Than Diabetes Drug for Achieving Pregnancy in Common Fertility Disorder
- GlaxoSmithKline Delivers Strong 2006 Performance with Full Year EPS Up 19% CER (16% Reported)
- SEC Charges Family With a $3.7 Million Insider Trading Scheme
- Pfizer's Sutent Receives FDA Approval to Include New First-Line Advanced Kidney Cancer Data in Label
February 9, 2007
- Gilead and Achillion Announce Positive Antiviral Activity of NS4A Antagonist in HCV, But Discontinue GS 9132 (ACH-806) Development
- Zeria, Kyowa Hakko in Japan Co-development and Co-marketing Agreement for Asacol for Inflammatory Bowel Disease
- Medal Program Showed Arthritis Patients Taking Arcoxia (etoricoxib) Experienced Significantly Fewer Upper Gastrointestinal Events Compared to Diclofenac
- Lovenox Patent Infringement Suit Decided Against Sanofi-Aventis
- Biota Holdings Announces Q2 Royalties from Relenza Grow to $7.3M
- Inflazyme Pharmaceuticals Announces Corporate Restructuring
- Nuvo Announces Update on Discussions With FDA Related to Approval of Pennsaid
- Genedata Expands Collaboration with HepatoSys Systems Biology Network
February 12, 2007
- NicOx Presents Promising Pre-Clinical Results on an NO-Donating Latanoprost Derivative From Its Glaucoma Collaboration With Pfizer
- Watson and GlaxoSmithKline Settle Lawsuit Over Wellbutrin Xl
- Adeza to Be Acquired by Cytyc for $24 Per Share
- AIDS Healthcare Foundation Bans Pfizer’s Drug Reps From Its Clinics
- Nexavar Shown to Significantly Extend Survival for Patients with Advanced Liver Cancer
- Forbes Medi-Tech Announces Next Steps in Pharmaceutical Development and Corporate Restructuring
- New Campaign Champions Changes in Medical Prescribing to End Conflicts of Interest
- Cell Therapeutics, Inc. Spin-off to Use Proprietary Recombinant Genetic Technology to Develop Novel Biopharmaceuticals
- FDA Announces Label and Indication Changes for the Antibiotic Ketek
- Sanofi-Aventis Announces Update to U.S. Prescribing Information for Ketek (Telithromycin)
- Commonwealth Biotechnologies, Inc. Completes Acquisition of Mimotopes Pty Ltd
- Ranbaxy Launches Atorvastatin in Denmark
February 13, 2007
- Multiple Articles in the New England Journal of Medicine Confirm On-Label, Long-Term Safety and Efficacy of the Cypher Sirolimus-Eluting Coronary Stent Compared to Bare Metal Stents
- Boston Scientific Welcomes New England Journal of Medicine Articles on Drug-Eluting Stents
- Johnson & Johnson Statement on Voluntary Disclosure
- Pfizer's Maraviroc to Receive Accelerated Regulatory Reviews in the U.S. and Europe
- Sanofi-aventis 2006: In a Difficult Environment, Another Year of Growth in Adjusted EPS Excluding Selected Items
- Teva Reports Fourth Quarter and Full Year 2006 Results
- Novartis, The Broad Institute, and Lund University Announce Release of Genome-wide Analysis of Genes Associated with Type 2 Diabetes and Related Metabolic Disorders
- Organon and Pharmacopeia Enter Into Discovery, Development and Commercialization Alliance
- Ingenuity Systems Announces Extension and Expansion of its Licensing Agreement with Merck
- ChemDiv to Provide Merck KGaA With Discovery Chemistry in Multiyear Agreement, Extending Ongoing Collaboration
- Generic Anti-Cholesterol Drugs Save $126 Million for Plan Sponsors, Patients
- Three Companies Consolidate under Holding Company
- Prescriptions for Cholesterol Drugs Rise with New Generics
February 14, 2007
- Study Published in The New England Journal of Medicine: 55 Percent Fewer Cases of Flu in Young Children Vaccinated With FluMist Vs. Flu Shot
- Merck Updates Prescribing Information for Rotateq, the Company's Vaccine to Help Prevent Rotavirus Gastroenteritis in Infants and Children
- Favrille Announces Agreement With Berlex, Inc. Regarding Use of FavId in Combination With Leukine (sargramostim) in B-Cell Non-Hodgkin's Lymphoma
- Halozyme And Baxter Expand Global Hylenex Collaboration
- Daiichi Sankyo Announces Midterm Management Plan for Fiscal 2007-2009
- Dainippon Sumitomo Pharma Co., Ltd.:Launch of 'Replagal 3.5 mg' for Anderson-Fabry Disease
- Genzyme Reports Financial Results for Fourth Quarter of 2006 and Full Year
- Merck Settles Tax Dispute with Internal Revenue Service
- Advancis Pharmaceutical Announces FDA Decision That its Amoxicillin Pulsys NDA is Not Complete
- Telik Announces Corporate Restructuring
- Biovail Issues Statement on Reports of Conclusion of SEC Gradient Investigation
- Eli Lilly and Company Statement: Judge Grants Lilly's Request for a Permanent Injunction Involving Misleading Selection of Illegally Leaked Lilly Documents
- Abraxis Bioscience Completes Acquisition of Manufacturing Complex from Pfizer
- Merck & Co., Inc., Again Reduces Price of Stocrin (efavirenz) for Patients in Least Developed Countries and Countries Hardest Hit by Epidemic
February 15, 2007
- Akzo Nobel Annual Results 2006: Record Year
- Biogen Idec Reports Full Year and Fourth Quarter 2006 Results
- Novartis Seeking Clarity in Indian Patent Laws, a Critical Incentive for Long-Term R&D Investments Into Better Medicines for Patients
- Sanofi pasteur to License Single Dose Japanese Encephalitis Vaccine from Acambis
- 2006 : Another Record Year for Solvay, Due to Strong Growth in Operating Performance
- FDA Accepts Two Supplemental New Drug Applications to Expand the U.S. Labeling for Januvia
- GlaxoSmithKline Extends Subsequent Offering Period By One Day
February 16, 2007
- FDA Alerts Consumers to Unsafe, Misrepresented Drugs Purchased Over the Internet
- Ranbaxy: Press Statement
- Wyeth Wins Little Rock Hormone Therapy Trial
- GPC Biotech Submits NDA for Lead Oncology Drug Candidate Satraplatin
- Closing of Boehringer Ingelheim`s Divestiture of Pharmaton SA to Ideasphere Cancelled
- First and Only Treatment Now Available for Mild-to-Moderate Parkinson's Disease Dementia
- Roche Files Application in Europe for Tamiflu 30 and 45 Mg Capsules
- GlaxoSmithKline Successfully Completes Tender Offer for Shares of Praecis Pharmaceuticals
- Advanced Magnetics Announces Settlement of Lawsuit with Cytogen Corporation
- InSite Vision Announces Patent Agreement With Pfizer
- Inspire Licenses AzaSite For Ocular Infections
- Anti-HIV Medication Prezista Receives Conditional Marketing Authorisation in the European Union
- European Approval of HIV Drug darunavir Will Provide a Potent New Option With Fuzeon for Treatment-Experienced Patients
- FDA Sends Abraxis BioScience Warning Letter Over Manufacturing Problems
February 19, 2007
- WHO reports some promising results on avian influenza vaccines
- Non-Insecticide Lice Treatment Kills Lice by Asphyxiation
February 20, 2007
- Shire plc: On Time Execution of Operating Plan Delivers Strong 2006 Performance
- Shire Agrees to Acquire New River to Gain Full Control of Vyvanse, its Future Flagship Product for ADHD
- New River Pharmaceuticals to be Acquired by Shire plc for $64 Per Share
- Shire Announces US$800 Million Equity Financing in Connection With Acquisition of New River
- New AARP Poll Shows 86% of Americans Over 18 Believe Medicare Should Have Bargaining Power for Prescription Drugs
- Bristol-Myers Squibb Completes Land Acquisition for New Biologics Facility
- SAFE Standard and Arcot Software Used By AstraZeneca to Submit First Digitally Signed Submission to FDA
- Entelos and Organon Extend Research Agreement
- Cancer Drug Can Extend Survival in Patients with Deadly Brain Tumors
- MIV Therapeutics Completes Acquisition of Biosync Scientific to Expand Operations and Accelerate Commercialization in Fast-Growing Markets
- Philadelphia Hormone Therapy Trial Completed
- Stem Cell Sciences Licenses Neural Stem Cell Technology to Merck & Co., Inc.
- Plaintiffs Win Another Prempro Case in Philadelphia; Wyeth Loses Second Hormone Therapy Drug Case
- FDA Warns About Erythropoiesis Stimulating Agents (ESAs) - Results of Aranesp Study May Apply to Other ESAs
February 21, 2007
- Pharmacyclics Receives Refuse to File Letter for Xcytrin
- King Pharmaceuticals Announces FDA Approval of New Bicillin Manufacturing Facility
- TransTech Pharma, Inc. Obtains Exclusive License to Glucokinase Activator Program for the Treatment of Diabetes from Novo Nordisk
- New Storage Instructions Approved for Byetta
- CSL Ltd.: Interim Result - Strong Profit from Operations, Up 46% to $257 Million
- Dyax and Genzyme Announce Agreement to Terminate Joint Venture for the Commercialization of DX-88 in HAE
- Vaccine Safety Group Releases Gardasil Reaction Report
- Merck KGaA: Karl-Ludwig Kley to Succeed Michael Roemer as Chairman of the Executive Board
- Access Pharmaceuticals Signs Letter of Intent to Acquire Somanta Pharmaceuticals
- Comprehensive Company, Brand, and Pipeline Database Now Provides Company-wide Access
- GlaxoSmithKline Advises Health Officials on Avandia
- PCMA: PBMs Negotiating Lower Drug Prices in Medicare Part D
- FDA Proposes to Strengthen Label Warning for Xolair
- FDA Directs ADHD Drug Manufacturers to Notify Patients about Cardiovascular Adverse Events and Psychiatric Adverse Events
- Though Most Physicians Support a Ban on Collecting Prescribing Information, Only a Fraction Have Used PDRP to Restrict Rx Data Access
- FDA MedWatch: Xolair (omalizumab) New Reports of Serious and Life-Threatening Allergic Reactions (anaphylaxis)
- Pennsylvania Attorney General Corbett Recovers $7.8 Million in Settlement Funds for State's Medicaid Program
February 22, 2007
- Lilly Introduces World's First Digital Insulin Pen With Memory
- Emergent BioSolutions Remains Committed to Development of Enhanced Anthrax Countermeasures
- AstraZeneca Announces Investment in $120m Laboratory for Process Research and Development at its Macclesfield Site, Cheshire, UK
- Sartorius AG Combines its Biotechnology Division with Stedim Biosystems S.A. and Becomes the Majority Owner of the Combined Entity
- Analysis of International Phase III Study of Avastin Plus Chemotherapy Shows Improved Progression-Free Survival in Patients With Advanced Lung Cancer
- Entelos Announces Continued Research with Pfizer
- Ark Wins Key Patent Case on Stroke in Europe
- Survey Shows Supreme Court Ruling May Hinder IP Licensing
- Lilly Introduces World's First Digital Insulin Pen With Memory
- Pharmaceutical Consumers & Marketers Surveyed to Assess Perceptions of Direct-to-Consumer Advertising in the Post-Vioxx Era
- Arpida Realigns Activities to Support Transition of Its Research Portfolio
- Ikaria and Investor Group to Acquire INO Therapeutics in $670 Million Cash and Stock Merger, Creating a World Leader in Critical Care Therapeutics
- Express Scripts and PCMA Follow-On Biologics Studies Are Based on Flawed Assumptions That Undermine Their Credibility: BIO Analysis Raises Serious Concerns Over Two Cost Savings Studies
February 23, 2007
- Danish Court Issues Preliminary Injunction That Prohibits Sale of Generic Lipitor Product
- Third Point Calls for Board to Sell Acorda Therapeutics, Inc.
- Astellas and Boehringer Won the Lawsuit Against FlomaxGeneric for Patent Infringement in the USA
- FDA MedWatch: CellCept Trial Terminated Due to Increased Incidence of Acute Rejection in Heart Transplant Patients Given Cellcept/Rapamune
- Recruitment Temporarily Suspended into C.E.R.A. Phase II Oncology Trial
February 26, 2007
- FDA Approves Cymbalta for Treatment of Generalized Anxiety Disorder
- Shire and New River Pharmaceuticals Announce FDA Approval of the First and Only Stimulant Prodrug Vyvanse (lisdexamfetamine dimesylate) as a Novel Treatment for ADHD
- Avalon Pharmaceuticals Announces the Initiation of the Primary Screening Phase in Drug Discovery Collaboration
- Novartis Committed to Making Galvus Available for Patients with Type 2 Diabetes After US Regulators Issue ''Approvable Letter''
- Lilly Plans New Clinical Trial of Xigris
- Drug Industry Increasingly Influences Breast Cancer Research
- FDA MedWatch: Baraclude Risk of Developing HIV Resistance Cannot be Excluded When Used in an HIV/HBV Co-infected Patient Not Receiving HAART
- Epix Reports Intention to Restate Financial Statements for Prior Fiscal Periods
- Inex Provides Timeline for Completing Spin-out of Tekmira Pharmaceuticals Corporation
- Graffinity and Amgen Enter into Drug Discovery Research Agreement
- Bristol-Myers Squibb Company and Adnexus Therapeutics Announce Collaboration to Develop and Commercialize Innovative Oncology Compounds
- Shire Extends Fosrenol | at Hand Program to Cover Medicare Part D Enrollees
- Azur Pharma Announces the Acquisition of Pharmelle
- GSK Initiates First Global Phase III Study of Tykerb (lapatinib) in Head and Neck Cancer
- Positive Recommendation for Avastin Use in Advanced or Recurrent Colorectal Cancer in Japan
- Phase 3 Stroke Trial Shows That Novoseven Reduces Bleeding in the Brain, but Does Not Improve Long-term Clinical Outcomes
- Takeda and TAP to Promote Sucampo's Amitiza in the United States
- BD Biosciences and Roche Collaborate to Advance the Study of Cell Signal Transduction through New Phosphorylation Site Antibody Targets and Applications
- VGX Pharmaceuticals and ADViSYS Announce Merger Agreement: Creation of VGX Immune Therapeutics Division
- Inex Pharmaceuticals Submits Petition Against Protiva Biotherapeutics
February 27, 2007
- Post-Hoc Data Analyses Published in Annals of Neurology Found Copaxone Significantly Delayed Accumulated Disability in Male Patients with Primary Progressive Multiple Sclerosis (PPMS)
- Vaccinex Announces Antibody Development and Commercialization Alliance in Multiple Sclerosis and Oncology
- Unigene Achieves $5.5 Million Milestone in Calcitonin Collaboration for Phase III Initiation
- inVentiv Health to Acquire Ignite Health, Leading Technology-Driven Healthcare Ad Agency
- Threshold Pharmaceuticals Announces That a Phase 3 Clinical Trial of Glufosfamide for Treatment of Pancreatic Cancer Did Not Meet Its Primary Endpoint
- Judgments Granted in Favor of Chugai in Lawsuits Filed by Ajinomoto Co., Inc.
- Increased Prescription Drug Co-pays Linked to Lower Medication Usage and Higher Hospitalization Rates, Thomson Medstat Study Finds
- AdMedia Partners Advises Ignite Health, an Interactive Healthcare Marketing Agency, in Acquisition by inVentiv Health
- More than 300 Medicines Now in Development to Treat Rare Diseases
- Mylan Provides an Update on Amlodipine Besylate Litigation
- FDA Approves New Treatment For Crohn's Disease
- Humira (Adalimumab) Receives FDA Approval For Treatment of Crohn's Disease
- Pfizer Wins Challenge to Norvasc Patent by Mylan
February 28, 2007
- FDA Approves First Drug To Prevent and Treat Vomiting in Dogs
- Merck Announces First Quarter Earnings Per Share Guidance and Raises Full-Year 2007 Earnings Per Share Guidance
- Avanir Pharmaceuticals Summarizes Outcome of FDA Meeting on Zenvia NDA
- American Heart Association Scientific Statement: AHA Statement Recommends Doctors Change Approach to Prescribing Pain Relievers for Patients With or at Risk for Heart Disease
- Epix Pharmaceuticals Files Formal Appeal for Vasovist with the Center for Drug Evaluation and Research
- Xoma Announces Expiration of Oncology Exclusivity Obligation With Novartis
- Barr Reports GAAP Loss For Three and Six Months Ended December 31, 2006 of $3.67 Per Share and $3.18 Per Share; Adjusted Earnings For Three and Six Months Were $0.83 Per Share and $1.70 Per Share
- Alnylam Scientist Awarded Two Industry Honors
- Daiichi Pharmaceutical (Beijing) Granted Sales Promotion Permission
- Novo Nordisk Divests Its Ownership of Dako's Business Activities
- King Pharmaceuticals Reports Year-End and Fourth-Quarter 2006 Financial Results
- UCB Full-Year 2006 Financial Results
- Salix Pharmaceuticals Acquires Pepcid Oral Suspension
- HPV Infection Common Among Females in U.S.
- Mylan Announces Launch of Quinapril Tablets, USP and Quinapril Hydrochloride and Hydrochlorothiazide Tablets
- King Pharmaceuticals Announces FDA Approval of Altace Tablet Formulation
- New Study: 'Show Me the Savings'
